| PDS Biotechnology is a clinical stage immuno-oncology company with a pipeline of clinical-stage immunotherapies to treat cancer at various stages, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Co.'s products are based on the proprietary Versamune® platform technology, which activates and directs the human immune system to unleash a targeted attack against cancer cells. The Versamune®-based immunotherapies may be used as monotherapies or in combination with other agents. Co.'s primary product, PDS0101 (Versamune®+HPV antigens), is designed to address human papillomavirus-associated cancers in its human clinical trial. The PDSB stock yearly return is shown above.
The yearly return on the PDSB stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2020 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the PDSB annual return calculation with any dividends reinvested as applicable (on ex-dates).